Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines

Clinical Cancer Research

Volumn 6, Issue 1, 2000, Pages 271-277

  Lu, Xiaohong ^a   Errington, Julie ^a   Chen, Victor J ^b   Curtin, Nicola J ^a   Boddy, Alan V ^a   Newell, David R ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; FOLIC ACID ANTAGONIST; LUCIFERASE; N [5 [2 (2 AMINO 1,4,5,6,7,8 HEXAHYDRO 4 OXOPYRIDO[2,3 D]PYRIMIDIN 6 YL)ETHYL] 2 THENOYL]GLUTAMIC ACID; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE;

ARTICLE; BIOLUMINESCENCE; CANCER CELL; CANCER INHIBITION; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PURINE SYNTHESIS;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL DIVISION; CELL SIZE; ENZYME INHIBITORS; FEMALE; HUMANS; HYDROXYMETHYL AND FORMYL TRANSFERASES; LUNG NEOPLASMS; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; TETRAHYDROFOLATES; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0033980769     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Habeck, L. L., Leitner, T. A., Shackelford, K. A., Gossett, L. S., Schultz, R. M., Andis, S. L., Shih, C., Grindey, G. B., and Mendelsohn, L. G. A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors. Cancer Res., 54: 1021-1026, 1994.
2. Beardsley, G. P., Moroson, B. A., Taylor, E. C., and Moran, R. G. A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis. J. Biol. Chem., 264: 328-333, 1989.
3. Mendelsohn, L. G., Shih, C., Schultz, R. M., and Worzalla, J. F. Biochemistry and pharmacology of glycinamide ribonucleotide formyl-transferase inhibitors: LY309887 and lometrexol. Investig. New Drugs, 14: 287-294, 1996.
4. Chen, V. J., Bewley, J. R., Andis, S. L., Schultz, R. M., Iversen, P. W., Shih, C., Mendelsohn, L. G., Seitz, D. E., and Tonkinson, J. L. Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. Br. J. Cancer, 78 (Suppl. 3): 27-34, 1998.
5. Young, C., Currie, V., Baltzer, L., Trochanowski, B., Eton, O., Dyke, R., and Bowsher, R. Phase I and clinical pharmacologic study of LY264618, 5,10-dideazatetrahydrofolate. Proc. Am. Assoc. Cancer Res., 31: 177, 1990.
6. Laohavinij, S., Wedge, S. R., Lind, M. J., Bailey, N., Humphreys, A., Proctor, M., Chapman, F., Simmons, D., Oakley, A., Robson, L., Gumbrell, L., Taylor, G. A., Thomas, H. D., Buddy, A. V., Newell, D. R., and Calvert, A. H. A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid. Investig. New Drugs, 14: 325-335, 1996.
7. Ray, M. S., Muggia, F. M., Leichman, C. G., Grunberg, S. M., Nelson, R. L., Dyke, R. W., and Moran, R. G. Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis. J. Natl. Cancer Inst., 85: 1154-1159, 1993.
8. Sessa, C., de Jong, J., D'Incalci, M., Hatty, S., Pagani, O., and Cavalli, F. Phase I study of the antipurine antifolate lometrexol (DDATHF) with folinic acid rescue. Clin. Cancer Res., 2: 1123-1127, 1996.
9. Young, C. W., Currie, V. E., Muindi, J. F., Saltz, L. B., Pisters, K. M. W., Esposito, A. J., and Dyke, R. W. Improved clinical tolerance of lometrexol with oral folic acid. Proc. Am. Assoc. Cancer Res., 33: 406, 1992.
10. Boritzki, T. J., Barlett, C. A., Zhang, C., Howland, E. F., Margosiak, S. A., Palmer, C. L., Romines, W. H., and Jackson, R. C. AG2034: a novel inhibitor of glycinamide ribonucleotide formyltransferase. Investig. New Drugs, 14: 295-303, 1996.
11. Chen, T. R. In situ detection of mycoplasma contamination in cell culture by fluorescent Hoechst 33258 stain. Exp. Cell Res., 104: 255-262, 1977.
12. Turner, R. N., Aherne, G. W., and Curtin, N. J. Selective potentiation of lometrexol growth inhibition by dipyridamole through cell-specific inhibition of hypoxanthine salvage. Br. J. Cancer, 76: 1300-1307, 1997.
13. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst., 82: 1107-1112, 1990.
14. Nguyen, V. T., Morange, M., and Bensaude, O. Firefly luciferase luminescence assays using scintillation counters for quantitation in transfected mammalian cells. Anal. Biochem., 171: 404-408, 1988.
15. Tonkinson, J. L., Marder, P., Andis, S. L., Schulz, R. M., Gossett, L. S., Shih, C., and Mendelsohn, L. G. Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis. Cancer Chemother. Pharmacol., 39: 521-531, 1997.
16. Smith, S. G., Lehman, N. L., and Moran, R. G. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells. Cancer Res., 53: 5697-5706, 1993.
17. Tse, A., and Moran R. G. Cellular folates prevent polyglutamation of 5,10-dideazatetrahydrofolate. J. Biol. Chem., 273: 25944-25952, 1998.
18. Eguchi, Y., Shimizu, S., and Tsujimoto, Y. Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Cancer Res., 57: 1835-1840, 1997.
19. Leist, M., Single, B., Castoldi, A. F., Kuhnle, S., and Nicotera, P. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J. Exp. Med., 185: 1481-1486, 1997.
20. Richter, C., Schweizer, M., Cossarizza, A., and Franceschi, C. Control of apoptosis by the cellular ATP level. FEBS Lett., 378: 107-110, 1996.
21. Smets, L. A., Van den Berg, J., Acton, D., Top, B., Van Rooij, H., and Verwijs-Janssen, M. BCL-2 expression and mitochondrial activity in leukemic cells with different sensitivity to glucocorticoid-induced apoptosis. Blood, 84: 1613-1619, 1994.
22. Lieberthal, W., Menza, S. A., and Levine, J. S. Graded ATP depletion can cause necrosis or apoptosis of cultured mouse proximal tubular cells. Am. J. Physiol., 274: F315-F327, 1998.
23. Green, D. R., and Reed, J. C. Mitochondria and apoptosis. Science (Washington DC), 281: 1309-1312, 1998.
24. O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sansville, E. A., Weinstein, J. N., Friend, S., Fornace, A. J., Jr., and Kohn, K. W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res., 57: 4285-4300, 1997.